ENVESTNET ASSET MANAGEMENT INC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 315 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.

Quarter-by-quarter ownership
ENVESTNET ASSET MANAGEMENT INC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$8,228,471
+60.5%
215,405
+51.5%
0.00%
+100.0%
Q2 2023$5,127,170
-13.3%
142,145
-51.3%
0.00%
-33.3%
Q1 2023$5,915,367
-26.7%
292,016
+105.9%
0.00%
-25.0%
Q4 2022$8,068,306
+59.4%
141,798
+10.7%
0.00%
+33.3%
Q3 2022$5,063,000
+63.9%
128,044
+82.3%
0.00%
+50.0%
Q2 2022$3,090,000
+19.8%
70,230
+8.6%
0.00%
+100.0%
Q1 2022$2,579,000
+5.5%
64,678
+6.4%
0.00%0.0%
Q4 2021$2,445,000
-1.3%
60,799
-0.1%
0.00%0.0%
Q3 2021$2,477,000
+17.0%
60,890
+30.6%
0.00%0.0%
Q2 2021$2,117,000
+16.9%
46,620
+7.3%
0.00%0.0%
Q1 2021$1,811,000
+53.2%
43,442
+57.0%
0.00%0.0%
Q4 2020$1,182,000
+58.7%
27,673
-2.4%
0.00%0.0%
Q3 2020$745,000
+79.1%
28,351
+82.5%
0.00%
Q2 2020$416,000
+47.0%
15,532
-1.1%
0.00%
Q1 2020$283,000
+6.4%
15,706
+4.6%
0.00%
Q4 2019$266,000
+19.3%
15,010
+4.4%
0.00%
Q3 2019$223,000
-7.5%
14,383
+2.5%
0.00%
Q2 2019$241,000
+8.6%
14,039
+2.0%
0.00%
Q1 2019$222,000
-15.9%
13,759
-23.8%
0.00%
Q4 2018$264,00018,053
+138769.2%
0.00%
Q4 2016$0
-100.0%
13
-99.2%
0.00%
Q1 2016$16,000
-36.0%
1,643
+16.2%
0.00%
Q4 2015$25,000
+78.6%
1,414
+39.2%
0.00%
Q3 2015$14,0001,0160.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q2 2021
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders